Viral Vector Manufacturing Market Research Report - Forecast till 2027

Viral Vector Manufacturing Market Research Report: by Type (Retroviral Vectors, Adenoviral Vectors and others), by Disease (Genetic Disorders, Infectious Diseases, and others), by Application (Gene Therapy, Vaccinology), by End User — Forecast till 2027

ID: MRFR/LS/5425-HCR | February 2021 | Region: Global | 90 pages

Viral Vector Manufacturing Market Scenario:


viral vector manufacturing market is expected to grow significantly over the forecast period. It is projected that the global viral vector manufacturing market is expected to register a CAGR Approx. 22.65% with an expected market value of USD 319 million during the forecast period of 2018–2023. Gene therapy is one of the preferred treatment options for most chronic diseases, involving insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors.


Numerous factors such as rise in number of clinical trials, increase in the number of gene therapy candidates, and growing necessity for an effective mode of disease treatment are expected to drive the growth of the market. Also, the characteristics of viral vectors such as ability to express therapeutic genes efficiently, and non-pathogenic nature fuels the growth of the market. Moreover, several companies involved in the development of viral agent-based products often seek support in terms of strategic collaborations and acquisitions with contract service providers to deliver a clinical grade product. This is mainly because of the limited availability and complexity of platform and technologies used for vector designing, production, packaging, and release testing. For example, in December 2017, Merck announced a commercial supply agreement to manufacture viral vectors for Bluebird Bio, Inc. for its use in potentially transformative gene therapies. This move will accentuate the life science business of Merck as a leading contract manufacturing organization and commercial provider of viral vectors for gene therapy.


However, high cost of gene therapies and possible mutagenesis may hamper the market growth during the assessment period.


Segmentation:


The viral vector manufacturing market has been segmented into type, disease, application, and end-user.


The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.


The segment, by retroviral vectors is anticipated to be the largest segment. Retro viruses contain an enzyme reverse transcriptase which allows the integration into the host genome. This has increased the usage of retroviral vectors in various treatment options, whereas the adenoviral vectors segment is estimated to be the fastest growing segment owing to their increased use in the in-vivo and in-vitro experiments.


The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.


The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.


The market, by application, has been segmented into gene therapy and vaccinology.


The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The viral vector manufacturing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European viral vector manufacturing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The viral vector manufacturing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The viral vector manufacturing market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players:


FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. are some of the key players in the global viral vector manufacturing market.


Regional Market Summary Global Viral Vector Manufacturing Market Share (%), by Region, 2017


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the global viral vector manufacturing market owing to a well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015.


Europe is expected to hold the second largest position in the global viral vector manufacturing market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the European Commission, in 2016 the total expenditure of the governments of the European Union on health amounted to 7.1% of GDP. Also, according to National Institute of Health Funding (NIHR) in the year 2016, a funding of Euro 928 million was announced for new NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research Facilities (CRF) for 5 years starting from April 2017.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.


On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.


Global Viral Vector Manufacturing Market, by Type



  • Retroviral Vectors

    • Lentiviral Vectors

    • Gamma-Retroviral Vectors



  • Adenoviral Vectors

  • Adeno-Associated Viral Vectors

  • Other Viral Vectors


Global Viral Vector Manufacturing Market, by Disease



  • Cancer

  • Genetic Disorders

  • Infectious Diseases

  • Others


Global Viral Vector Manufacturing Market, by Application



  • Gene Therapy

  • Vaccinology


Global Viral Vector Manufacturing Market, by End-user



  • Pharmaceutical and Biotechnology Companies

  • Research Institutes

  • Others


Global Viral Vector Manufacturing Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • The Middle East & Africa

    • Middle East

    • Africa




Global Viral Vector Manufacturing Market, by Key Players



  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

  • Sanofi

  • Lonza

  • Merck KGaA

  • GENERAL ELECTRIC COMPANY

  • Oxford BioMedica

  • Spark Therapeutics, Inc.

  • uniQure N.V.

  • FinVector Vision Therapies

  • Brammer Bio

  • Cell and Gene Therapy Catapult

  • Cobra Biologics

  • REGENXBIO Inc.

  • Kaneka Eurogentec S.A.


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Private Research institutes

  • Diagnostic Laboratories

  • Government Research Institutes

  • Academic Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 319 Million
  • 2027: Significant Value
  •   CAGR   22.65% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Disease, Application, and End-user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A.
      Key Market Opportunities

  • Rise in number of clinical trials
  • Increase in the number of gene therapy candidates
  • Growing necessity for an effective mode of disease treatment
  •   Key Market Drivers

  • Ability to express therapeutic genes efficiently
  • Non-pathogenic nature


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    On the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.

    Viruses that are often used as vectors include retroviruses that integrate their genetic material including the new gene in the human cell, and adenoviruses, that introduce their DNA into the nucleus of the cell without letting the DNA to integrate into a chromosome. These viruses are modified so they can't cause disease when used in people.

    Viral Vector Manufacturing Market would register USD 319 million valuations by 2023.

    Viral Vector Manufacturing Market would proceed with 22.65% CAGR during the forecast period of 2018 to 2023.

    Viral Vector Manufacturing Market could be hampered by costly gene therapies and possible mutagenesis.

    Retroviral segment would lead to the Viral Vector Manufacturing Market.

    Americas would head the Viral Vector Manufacturing Market.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Viral Vector Manufacturing Market, by Type

    6.1 Introduction

    6.2 Retroviral Vectors

    6.2.1 Lentiviral Vectors

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.2.2 Gamma-Retroviral Vectors

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3 Adenoviral Vectors

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4 Adeno-Associated Viral Vectors

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5 Other Viral Vectors

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 7. Global Viral Vector Manufacturing Market, by Disease

    7.1 Introduction

    7.2 Cancer

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3 Genetic Disorders

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4 Infectious Diseases

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.5 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8. Global Viral Vector Manufacturing Market, by Application

    8.1 Introduction

    8.2 Gene Therapy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Vaccinology

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 9. Global Viral Vector Manufacturing Market, By End-user

    9.1 Introduction

    9.2 Pharmaceutical and Biotechnology Companies

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.3 Research Institutes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    9.4 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 10. Global Viral Vector Manufacturing Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12. Company Profiles

    12.1 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Sanofi

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Lonza

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Merck KGaA

    12.4.1 Company Overview

    12.4.2 Product Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 UNIQURE N.V.

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Oxford BioMedica

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Spark Therapeutics, Inc.

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 UniQure N.V.

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 FinVector Vision Therapies

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Brammer Bio

    12.10.1 Overview

    12.10.2 Product Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Cell and Gene Therapy Catapult

    12.11.1 Overview

    12.11.2 Product Overview

    12.11.3 Financials

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.12 Cobra Biologics

    12.12.1 Overview

    12.12.2 Product Overview

    12.12.3 Financials

    12.12.4 Key Developments

    12.12.5 SWOT Analysis

    12.13 REGENXBIO Inc.

    12.13.1 Overview

    12.13.2 Product Overview

    12.13.3 Financials

    12.13.4 Key Developments

    12.13.5 SWOT Analysis

    12.14 Kaneka Eurogentec S.A.

    12.14.1 Overview

    12.14.2 Product Overview

    12.14.3 Financials

    12.14.4 Key Developments

    12.14.5 SWOT Analysis

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Predictions for the Viral Vector Manufacturing Industry

    Chapter 14. Appendix


    LIST OF TABLES

    Table 1 Global Viral Vector Manufacturing Market Synopsis, 2020-2027

    Table 2 Global Viral Vector Manufacturing Market Estimates and Forecast, 2020-2027 (USD Million)

    Table 3 Global Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 4 Global Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 5 Global Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 6 Global Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 7 Global Viral Vector Manufacturing Market, by Region, 2020-2027(USD Million)

    Table 8 North America: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 9 North America: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 10 North America: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 11 North America: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 12 North America: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    Table 13 US: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 14 US: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 15 US: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 16 US: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 17 US: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    Table 18 Canada: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 19 Canada: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 20 Canada: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 21 Canada: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 22 Canada: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    Table 23 South America: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 24 South America: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 25 South America: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 26 South America: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 27 South America: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    Table 28 Europe: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 29 Europe: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 30 Europe: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 31 Europe: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 32 Europe: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    Table 33 Western Europe: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 34 Western Europe: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 35 Western Europe: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 36 Western Europe: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 37 Western Europe: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    Table 38 Eastern Europe: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 39 Eastern Europe: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 40 Eastern Europe: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 41 Eastern Europe: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 42 Eastern Europe: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    Table 43 Asia-Pacific: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 44 Asia-Pacific: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 45 Asia-Pacific: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 46 Asia-Pacific: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 47 Asia-Pacific: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    Table 48 Middle East & Africa: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

    Table 49 Middle East & Africa: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

    Table 50 Middle East & Africa: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

    Table 51 Middle East & Africa: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

    Table 52 Middle East & Africa: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Viral Vector Manufacturing Market

    Figure 3 Segmentation Market Dynamics for Global Viral Vector Manufacturing Market

    Figure 4 Global Viral Vector Manufacturing Market Share, by Type, 2020 (%)

    Figure 5 Global Viral Vector Manufacturing Market Share, by Disease, 2020 (%)

    Figure 6 Global Viral Vector Manufacturing Market Share, by Application, 2020 (%)

    Figure 7 Global Viral Vector Manufacturing Market Share, by End-User, 2020 (%)

    Figure 8 Global Viral Vector Manufacturing Market Share, by Region, 2020 (%)

    Figure 9 North America: Viral Vector Manufacturing Market Share, by Country, 2020 (%)

    Figure 10 Europe: Viral Vector Manufacturing Market Share, by Country, 2020 (%)

    Figure 11 Asia-Pacific: Viral Vector Manufacturing Market Share, by Country, 2020 (%)

    Figure 12 Middle East & Africa: Viral Vector Manufacturing Market Share, by Country, 2020 (%)

    Figure 13 Global Viral Vector Manufacturing Market: Company Share Analysis, 2020 (%)

    Figure 14 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.: Key Financials

    Figure 15 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.: Segmental Revenue

    Figure 16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.: Geographical Revenue

    Figure 17 Sanofi: Key Financials

    Figure 18 Sanofi: Segmental Revenue

    Figure 19 Sanofi: Geographical Revenue

    Figure 20 Lonza: Key Financials

    Figure 21 Lonza: Segmental Revenue

    Figure 22 Lonza: Geographical Revenue

    Figure 23 Merck KGaA: Key Financials

    Figure 24 Merck KGaA: Segmental Revenue

    Figure 25 Merck KGaA: Geographical Revenue

    Figure 26 UNIQURE N.V.: Key Financials

    Figure 27 UNIQURE N.V.: Segmental Revenue

    Figure 28 UNIQURE N.V.: Geographical Revenue

    Figure 29 Oxford BioMedica: Key Financials

    Figure 30 Oxford BioMedica: Segmental Revenue

    Figure 31 Oxford BioMedica: Geographical Revenue

    Figure 32 Spark Therapeutics, Inc.: Key Financials

    Figure 33 Spark Therapeutics, Inc.: Segmental Revenue

    Figure 34 Spark Therapeutics, Inc.: Geographical Revenue

    Figure 35 UniQure N.V.: Key Financials

    Figure 36 UniQure N.V.: Segmental Revenue

    Figure 37 UniQure N.V.: Geographical Revenue

    Figure 38 FinVector Vision Therapies: Key Financials

    Figure 39 FinVector Vision Therapies: Segmental Revenue

    Figure 40 FinVector Vision Therapies: Geographical Revenue

    Figure 41 Brammer Bio: Key Financials

    Figure 42 Brammer Bio: Segmental Revenue

    Figure 43 Brammer Bio: Geographical Revenue

    Figure 44 Cell and Gene Therapy Catapult: Key Financials

    Figure 45 Cell and Gene Therapy Catapult: Segmental Revenue

    Figure 46 Cell and Gene Therapy Catapult: Geographical Revenue

    Figure 47 Cobra Biologics: Key Financials

    Figure 48 Cobra Biologics: Segmental Revenue

    Figure 49 Cobra Biologics: Geographical Revenue

    Figure 50 REGENXBIO Inc.: Key Financials

    Figure 51 REGENXBIO Inc.: Segmental Revenue

    Figure 52 REGENXBIO Inc.: Geographical Revenue

    Figure 53 Kaneka Eurogentec S.A.: Key Financials

    Figure 54 Kaneka Eurogentec S.A.: Segmental Revenue

    Figure 55 Kaneka Eurogentec S.A.: Geographical Revenue